199 related articles for article (PubMed ID: 29722825)
1. Feasibility of split-course stereotactic ablative radiotherapy for oligometastases.
Paik EK; Kim MS; Seo YS; Jang WI; Kang JK; Cho CK; Yoo HJ
Jpn J Clin Oncol; 2018 Jun; 48(6):548-554. PubMed ID: 29722825
[TBL] [Abstract][Full Text] [Related]
2. Should organs at risk (OARs) be prioritized over target volume coverage in stereotactic ablative radiotherapy (SABR) for oligometastases? a secondary analysis of the population-based phase II SABR-5 trial.
Eufemon Cereno R; Mou B; Baker S; Chng N; Arbour G; Bergman A; Liu M; Schellenberg D; Matthews Q; Huang V; Mestrovic A; Hyde D; Alexander A; Carolan H; Hsu F; Miller S; Atrchian S; Chan E; Ho C; Mohamed I; Lin A; Berrang T; Bang A; Jiang W; Lund C; Pai H; Valev B; Lefresne S; Tyldesley S; Olson RA
Radiother Oncol; 2023 May; 182():109576. PubMed ID: 36822355
[TBL] [Abstract][Full Text] [Related]
3. Total tumor volume as a predictor of survival in patients with multiple oligometastases treated with stereotactic ablative radiotherapy (SABR).
Franzese C; Vernier V; Franceschini D; Comito T; Navarria P; Clerici E; Teriaca MA; Massaro M; Di Cristina L; Marini B; Galdieri C; Mancosu P; Tomatis S; Scorsetti M
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10495-10503. PubMed ID: 37280407
[TBL] [Abstract][Full Text] [Related]
4. Stereotactic ablative radiotherapy for oligometastatic disease in liver.
Kim M; Son SH; Won YK; Kay CS
Biomed Res Int; 2014; 2014():340478. PubMed ID: 24868526
[TBL] [Abstract][Full Text] [Related]
5. Population-based phase II trial of stereotactic ablative radiotherapy (SABR) for up to 5 oligometastases: SABR-5.
Olson R; Liu M; Bergman A; Lam S; Hsu F; Mou B; Berrang T; Mestrovic A; Chng N; Hyde D; Matthews Q; Lund C; Glick D; Pai H; Basran P; Carolan H; Valev B; Lefresene S; Tyldesley S; Schellenberg D
BMC Cancer; 2018 Oct; 18(1):954. PubMed ID: 30286739
[TBL] [Abstract][Full Text] [Related]
6. Second Chance for Cure: Stereotactic Ablative Radiotherapy in Oligometastatic Disease.
Salim N; Tumanova K; Popodko A; Libson E
JCO Glob Oncol; 2024 May; 10():e2300275. PubMed ID: 38754052
[TBL] [Abstract][Full Text] [Related]
7. Increased efficacy of stereotactic ablative radiation therapy after bevacizumab in lung oligometastases from colon cancer.
Mazzola R; Tebano U; Aiello D; Paola GD; Giaj-Levra N; Ricchetti F; Fersino S; Fiorentino A; Ruggieri R; Alongi F
Tumori; 2018 Dec; 104(6):423-428. PubMed ID: 29737958
[TBL] [Abstract][Full Text] [Related]
8. Hypofractionated image-guided breath-hold SABR (stereotactic ablative body radiotherapy) of liver metastases--clinical results.
Boda-Heggemann J; Dinter D; Weiss C; Frauenfeld A; Siebenlist K; Attenberger U; Ottstadt M; Schneider F; Hofheinz RD; Wenz F; Lohr F
Radiat Oncol; 2012 Jun; 7():92. PubMed ID: 22710033
[TBL] [Abstract][Full Text] [Related]
9. Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach.
Comito T; Cozzi L; Clerici E; Campisi MC; Liardo RL; Navarria P; Ascolese A; Tozzi A; Iftode C; De Rose F; Villa E; Personeni N; Rimassa L; Santoro A; Fogliata A; Mancosu P; Tomatis S; Scorsetti M
BMC Cancer; 2014 Aug; 14():619. PubMed ID: 25163798
[TBL] [Abstract][Full Text] [Related]
10. Predictors of Local Control for Stereotactic Ablative Radiotherapy (SAbR) in Pulmonary Oligometastases from Gastrointestinal Malignancies.
Simoni N; Micera R; Rossi G; Giri MG; Pavarana M; Muraglia A; Cernusco NLV; DE Liguoro M; Guariglia S; Cavedon C; Milella M; Mazzarotto R
Anticancer Res; 2020 Oct; 40(10):5901-5907. PubMed ID: 32988921
[TBL] [Abstract][Full Text] [Related]
11. Disease course of lung oligometastatic colorectal cancer treated with stereotactic body radiotherapy.
Nicosia L; Cuccia F; Mazzola R; Ricchetti F; Figlia V; Giaj-Levra N; Rigo M; Tomasini D; Pasinetti N; Corradini S; Ruggieri R; Alongi F
Strahlenther Onkol; 2020 Sep; 196(9):813-820. PubMed ID: 32399637
[TBL] [Abstract][Full Text] [Related]
12. Consolidative stereotactic ablative radiotherapy (SABR) to intrapulmonary lesions is associated with prolonged progression-free survival and overall survival in oligometastatic NSCLC patients: A prospective phase 2 study.
Blake-Cerda M; Lozano-Ruíz F; Maldonado-Magos F; de la Mata-Moya D; Díaz-García D; Lara-Mejía L; Zatarain-Barrón ZL; Cuevas-Góngora MF; Barron-Barron F; Corona-Cruz JF; Cabrera-Miranda L; Arroyo-Hernández M; Gerson R; Arrieta O
Lung Cancer; 2021 Feb; 152():119-126. PubMed ID: 33385737
[TBL] [Abstract][Full Text] [Related]
13. Feasible Optimization of Stereotactic Ablative Radiotherapy Dose by Tumor Size for Stage I Non-small-cell Lung Cancer.
Lee S; Song SY; Kim SS; Choi W; Je HU; Back GM; Cho B; Jeong SY; Choi EK
Clin Lung Cancer; 2018 Mar; 19(2):e253-e261. PubMed ID: 29196082
[TBL] [Abstract][Full Text] [Related]
14. Single Fraction Stereotactic Ablative Body Radiotherapy for Oligometastasis: Outcomes from 132 Consecutive Patients.
Gandhidasan S; Ball D; Kron T; Bressel M; Shaw M; Chu J; Chander S; Wheeler G; Plumridge N; Chesson B; David S; Siva S
Clin Oncol (R Coll Radiol); 2018 Mar; 30(3):178-184. PubMed ID: 29224900
[TBL] [Abstract][Full Text] [Related]
15. Treatment With Stereotactic Ablative Radiotherapy for Up to 5 Oligometastases in Patients With Cancer: Primary Toxic Effect Results of the Nonrandomized Phase 2 SABR-5 Clinical Trial.
Olson R; Jiang W; Liu M; Bergman A; Schellenberg D; Mou B; Alexander A; Carolan H; Hsu F; Miller S; Atrchian S; Chan E; Ho C; Mohamed I; Lin A; Berrang T; Bang A; Chng N; Matthews Q; Baker S; Huang V; Mestrovic A; Hyde D; Lund C; Pai H; Valev B; Lefresene S; Tyldesley S
JAMA Oncol; 2022 Nov; 8(11):1644-1650. PubMed ID: 36173619
[TBL] [Abstract][Full Text] [Related]
16. Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature.
Ong WL; Koh TL; Lim Joon D; Chao M; Farrugia B; Lau E; Khoo V; Lawrentschuk N; Bolton D; Foroudi F
BJU Int; 2019 Nov; 124 Suppl 1():19-30. PubMed ID: 31507035
[TBL] [Abstract][Full Text] [Related]
17. Treatment outcomes of stereotactic ablative body radiotherapy on oligometastases from colorectal cancer: early results of a single institution service evaluation.
Duong J; Stewart-Lord A; Nariyangadu P; Harrison M; Tsang YM
BJR Open; 2022; 4(1):20210071. PubMed ID: 36105422
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic Ablative Radiation Therapy for Lung Oligometastases: Predictive Parameters of Early Response by
Mazzola R; Fiorentino A; Di Paola G; Giaj Levra N; Ricchetti F; Fersino S; Tebano U; Pasetto S; Ruggieri R; Salgarello M; Alongi F
J Thorac Oncol; 2017 Mar; 12(3):547-555. PubMed ID: 28126325
[TBL] [Abstract][Full Text] [Related]
19. Curative intent Stereotactic Ablative Radiation Therapy (SABR) for treatment of lung oligometastases from head and neck squamous cell carcinoma (HNSCC): a multi-institutional retrospective study.
Debbi K; Loganadane G; To NH; Kinj R; Husain ZA; Chapet S; Nguyen NP; Barillot I; Benezery K; Belkacemi Y; Calais G
Br J Radiol; 2022 May; 95(1133):20210033. PubMed ID: 35143326
[TBL] [Abstract][Full Text] [Related]
20. Local Recurrence Outcomes of Colorectal Cancer Oligometastases Treated With Stereotactic Ablative Radiotherapy.
Benson KRK; Sandhu N; Zhang C; Ko R; Toesca DAS; Lee PE; Von Eyben R; Diehn M; Gensheimer M; Maxim PG; Bush K; Loo BW; Soltys SG; Pollom EL; Chang DT
Am J Clin Oncol; 2021 Nov; 44(11):559-564. PubMed ID: 34534143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
